{"id":53898,"date":"2026-01-13T14:09:54","date_gmt":"2026-01-13T06:09:54","guid":{"rendered":"https:\/\/flcube.com\/?p=53898"},"modified":"2026-01-13T14:09:55","modified_gmt":"2026-01-13T06:09:55","slug":"broncus-medical-secures-nmpa-fast-track-for-bronctarget-copd-system-targeting-9-million-refractory-patients-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53898","title":{"rendered":"Broncus Medical Secures NMPA Fast\u2011Track for BroncTarget COPD System, Targeting 9\u202fMillion Refractory Patients in China"},"content":{"rendered":"\n<p><strong>Broncus Medical<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2216:HKG\">HKG:\u202f2216<\/a>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has granted <strong>fast\u2011track designation<\/strong> for its <strong>BroncTarget lung targeted denervation (TLD) radiofrequency ablation system<\/strong>, a first\u2011in\u2011class bronchoscopic intervention for <strong>moderate\u2011to\u2011severe chronic obstructive pulmonary disease (COPD)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Fast\u2011track<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>BroncTarget TLD System<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Moderate\u2011to\u2011severe COPD (adjunct to standard therapy)<\/td><\/tr><tr><td><strong>Date of Designation<\/strong><\/td><td>8\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Clinical Trial Status<\/strong><\/td><td>Confirmatory trial ongoing; 28 hospitals actively recruiting<\/td><\/tr><tr><td><strong>Next Milestone<\/strong><\/td><td>NDA submission expected H2\u202f2027<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile\">Technology Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism of Action:<\/strong> Delivers <strong>radiofrequency energy<\/strong> via bronchoscopy to ablate parasympathetic nerves supplying the airways, suppressing <strong>abnormal bronchoconstriction and mucus hypersecretion<\/strong> at the source<\/li>\n\n\n\n<li><strong>Clinical Rationale:<\/strong> Addresses <strong>drug\u2011refractory symptoms<\/strong> (cough, sputum, dyspnea) in patients inadequately controlled by LAMA\/LABA\/ICS therapy alone<\/li>\n\n\n\n<li><strong>Key Innovations:<\/strong><\/li>\n\n\n\n<li><strong>Circular multi\u2011electrode array<\/strong> with <strong>adjustable loop diameter<\/strong> (18\u201125\u202fmm) for anatomical customization<\/li>\n\n\n\n<li><strong>Differentiated RF energy output<\/strong> with <strong>real\u2011time temperature\/impedance monitoring<\/strong> to prevent airway injury<\/li>\n\n\n\n<li><strong>Intelligent cold saline perfusion<\/strong> for active cooling, ensuring <strong>precise lesion formation<\/strong> while preserving mucosal integrity<\/li>\n\n\n\n<li><strong>Procedure Time:<\/strong> ~45\u202fminutes under moderate sedation; <strong>day\u2011case discharge<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-amp-evidence\">Clinical Development &amp; Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Status\/Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Trial Design<\/strong><\/td><td>Prospective, multicenter, single\u2011arm confirmatory study (n\u202f=\u202f180)<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Change in FEV\u2081 (forced expiratory volume) at 12\u202fmonths<\/td><\/tr><tr><td><strong>Secondary Endpoints<\/strong><\/td><td>CAT score, SGRQ, 6\u2011minute walk distance, exacerbation rate<\/td><\/tr><tr><td><strong>Enrollment Status<\/strong><\/td><td>142 patients enrolled; 28 tertiary hospitals recruiting<\/td><\/tr><tr><td><strong>Pilot Data (n\u202f=\u202f45)<\/strong><\/td><td>+12\u202f% FEV\u2081 improvement, 58\u202f% reduction in exacerbations, 0\u202f% grade\u202f\u2265\u202f3 pneumothorax<\/td><\/tr><tr><td><strong>Competitive Edge<\/strong> vs. <strong>Nuvaira\u2019s TLD<\/strong> (US investigational)<\/td><td>BroncTarget offers <strong>smaller catheter profile (6\u202fmm vs. 8\u202fmm)<\/strong> and <strong>shorter procedure time<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-revenue-forecast\">Market Opportunity &amp; Revenue Forecast<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>China COPD Prevalence<\/strong><\/td><td>100\u202fmillion<\/td><td>102\u202fmillion<\/td><td>104\u202fmillion<\/td><\/tr><tr><td><strong>Moderate\u2011to\u2011Severe Cases<\/strong><\/td><td>30\u202fmillion<\/td><td>30.6\u202fmillion<\/td><td>31.2\u202fmillion<\/td><\/tr><tr><td><strong>Drug\u2011Refractory (Eligible)<\/strong><\/td><td>9\u202fmillion<\/td><td>9.2\u202fmillion<\/td><td>9.4\u202fmillion<\/td><\/tr><tr><td><strong>BroncTarget Market Penetration<\/strong><\/td><td>0\u202f%<\/td><td>0.02\u202f%<\/td><td>0.15\u202f%<\/td><\/tr><tr><td><strong>Annual Procedure Volume<\/strong><\/td><td>\u2013<\/td><td>1,840<\/td><td>14,100<\/td><\/tr><tr><td><strong>Device Price (\u00a5)<\/strong><\/td><td>\u2013<\/td><td>\u00a568,000<\/td><td>\u00a565,000<\/td><\/tr><tr><td><strong>China Revenue Forecast<\/strong><\/td><td>\u2013<\/td><td>\u00a5125\u202fmillion<\/td><td>\u00a5917\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Health Economics:<\/strong> TLD procedure reduces annual COPD\u2011related hospitalizations by <strong>1.8\u202fdays\/patient<\/strong>, saving ~\u00a524,000 in direct costs; <strong>ROI &lt;\u202f18\u202fmonths<\/strong> for hospitals<\/li>\n\n\n\n<li><strong>Reimbursement Pathway:<\/strong> NMPA fast\u2011track enables <strong>priority NRDL negotiation<\/strong> in 2028; expected reimbursement at <strong>\u00a545,000\u201150,000<\/strong> (65\u202f% coverage)<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> Broncus plans <strong>FDA IDE filing<\/strong> in 2028, targeting US COPD market (15\u202fmillion eligible patients)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company\/Product<\/th><th>Stage<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Broncus\/BroncTarget<\/strong><\/td><td>Phase\u202fIII (China)<\/td><td>Only system with <strong>adjustable loop<\/strong> and <strong>saline perfusion<\/strong><\/td><\/tr><tr><td><strong>Nuvaira\/Nuvaira System<\/strong><\/td><td>Phase\u202fIII (US)<\/td><td>Larger catheter, longer procedure<\/td><\/tr><tr><td><strong>Boston Scientific<\/strong><\/td><td>Preclinical<\/td><td>RF balloon technology, earlier stage<\/td><\/tr><tr><td><strong>Standard of Care<\/strong><\/td><td>Marketed<\/td><td>LAMA\/LABA\/ICS triple therapy; no interventional option<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Dual\u2011site production in <strong>Shanghai<\/strong> and <strong>San Jose<\/strong>; capacity scaled to 5,000 units\/year by 2027<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> 28 granted patents covering electrode geometry, RF algorithms, and saline cooling; <strong>freedom\u2011to\u2011operate<\/strong> in US and EU confirmed<\/li>\n\n\n\n<li><strong>Commercial Partnership:<\/strong> Negotiations underway with <strong>Mindray<\/strong> for distribution in 300 tier\u20112\/3 hospitals<\/li>\n\n\n\n<li><strong>Pipeline Extension:<\/strong> Broncus developing <strong>TLD+<\/strong> with integrated drug\u2011eluting capability for asthma (Phase\u202fI 2027)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding BroncTarget\u2019s clinical trial outcomes, NMPA approval timeline, and revenue projections. Actual results may differ due to competitive dynamics, reimbursement negotiations, and unforeseen safety signals.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011201192_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026011201192_c.\"><\/object><a id=\"wp-block-file--media-46fa6279-20d5-4c97-9079-1fe9803e45fe\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011201192_c.pdf\">2026011201192_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011201192_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-46fa6279-20d5-4c97-9079-1fe9803e45fe\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Broncus Medical (HKG:\u202f2216) announced that China\u2019s National Medical Products Administration (NMPA) has granted fast\u2011track designation&#8230;<\/p>\n","protected":false},"author":1,"featured_media":53902,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[1287,1288,38],"class_list":["post-53898","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-medical-device","tag-broncus-medical","tag-hkg-2216","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Broncus Medical Secures NMPA Fast\u2011Track for BroncTarget COPD System, Targeting 9\u202fMillion Refractory Patients in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Broncus Medical (HKG:\u202f2216) announced that China\u2019s National Medical Products Administration (NMPA) has granted fast\u2011track designation for its BroncTarget lung targeted denervation (TLD) radiofrequency ablation system, a first\u2011in\u2011class bronchoscopic intervention for moderate\u2011to\u2011severe chronic obstructive pulmonary disease (COPD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53898\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Broncus Medical Secures NMPA Fast\u2011Track for BroncTarget COPD System, Targeting 9\u202fMillion Refractory Patients in China\" \/>\n<meta property=\"og:description\" content=\"Broncus Medical (HKG:\u202f2216) announced that China\u2019s National Medical Products Administration (NMPA) has granted fast\u2011track designation for its BroncTarget lung targeted denervation (TLD) radiofrequency ablation system, a first\u2011in\u2011class bronchoscopic intervention for moderate\u2011to\u2011severe chronic obstructive pulmonary disease (COPD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53898\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-13T06:09:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-13T06:09:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1305.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53898#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53898\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Broncus Medical Secures NMPA Fast\u2011Track for BroncTarget COPD System, Targeting 9\u202fMillion Refractory Patients in China\",\"datePublished\":\"2026-01-13T06:09:54+00:00\",\"dateModified\":\"2026-01-13T06:09:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53898\"},\"wordCount\":513,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53898#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1305.webp\",\"keywords\":[\"Broncus Medical\",\"HKG: 2216\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53898#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53898\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53898\",\"name\":\"Broncus Medical Secures NMPA Fast\u2011Track for BroncTarget COPD System, Targeting 9\u202fMillion Refractory Patients in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53898#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53898#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1305.webp\",\"datePublished\":\"2026-01-13T06:09:54+00:00\",\"dateModified\":\"2026-01-13T06:09:55+00:00\",\"description\":\"Broncus Medical (HKG:\u202f2216) announced that China\u2019s National Medical Products Administration (NMPA) has granted fast\u2011track designation for its BroncTarget lung targeted denervation (TLD) radiofrequency ablation system, a first\u2011in\u2011class bronchoscopic intervention for moderate\u2011to\u2011severe chronic obstructive pulmonary disease (COPD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53898#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53898\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53898#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1305.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1305.webp\",\"width\":1080,\"height\":608,\"caption\":\"Broncus Medical Secures NMPA Fast\u2011Track for BroncTarget COPD System, Targeting 9\u202fMillion Refractory Patients in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53898#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Broncus Medical Secures NMPA Fast\u2011Track for BroncTarget COPD System, Targeting 9\u202fMillion Refractory Patients in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Broncus Medical Secures NMPA Fast\u2011Track for BroncTarget COPD System, Targeting 9\u202fMillion Refractory Patients in China - Insight, China&#039;s Pharmaceutical Industry","description":"Broncus Medical (HKG:\u202f2216) announced that China\u2019s National Medical Products Administration (NMPA) has granted fast\u2011track designation for its BroncTarget lung targeted denervation (TLD) radiofrequency ablation system, a first\u2011in\u2011class bronchoscopic intervention for moderate\u2011to\u2011severe chronic obstructive pulmonary disease (COPD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53898","og_locale":"en_US","og_type":"article","og_title":"Broncus Medical Secures NMPA Fast\u2011Track for BroncTarget COPD System, Targeting 9\u202fMillion Refractory Patients in China","og_description":"Broncus Medical (HKG:\u202f2216) announced that China\u2019s National Medical Products Administration (NMPA) has granted fast\u2011track designation for its BroncTarget lung targeted denervation (TLD) radiofrequency ablation system, a first\u2011in\u2011class bronchoscopic intervention for moderate\u2011to\u2011severe chronic obstructive pulmonary disease (COPD).","og_url":"https:\/\/flcube.com\/?p=53898","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-13T06:09:54+00:00","article_modified_time":"2026-01-13T06:09:55+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1305.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53898#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53898"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Broncus Medical Secures NMPA Fast\u2011Track for BroncTarget COPD System, Targeting 9\u202fMillion Refractory Patients in China","datePublished":"2026-01-13T06:09:54+00:00","dateModified":"2026-01-13T06:09:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53898"},"wordCount":513,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=53898#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1305.webp","keywords":["Broncus Medical","HKG: 2216","Market approval filings"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53898#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53898","url":"https:\/\/flcube.com\/?p=53898","name":"Broncus Medical Secures NMPA Fast\u2011Track for BroncTarget COPD System, Targeting 9\u202fMillion Refractory Patients in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=53898#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=53898#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1305.webp","datePublished":"2026-01-13T06:09:54+00:00","dateModified":"2026-01-13T06:09:55+00:00","description":"Broncus Medical (HKG:\u202f2216) announced that China\u2019s National Medical Products Administration (NMPA) has granted fast\u2011track designation for its BroncTarget lung targeted denervation (TLD) radiofrequency ablation system, a first\u2011in\u2011class bronchoscopic intervention for moderate\u2011to\u2011severe chronic obstructive pulmonary disease (COPD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53898#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53898"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=53898#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1305.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1305.webp","width":1080,"height":608,"caption":"Broncus Medical Secures NMPA Fast\u2011Track for BroncTarget COPD System, Targeting 9\u202fMillion Refractory Patients in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53898#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Broncus Medical Secures NMPA Fast\u2011Track for BroncTarget COPD System, Targeting 9\u202fMillion Refractory Patients in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1305.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53898","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53898"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53898\/revisions"}],"predecessor-version":[{"id":53903,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53898\/revisions\/53903"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/53902"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53898"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53898"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53898"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}